• SIGN IN
  • GET HELP
  •  

    Home Study Details


    Program Type

    Home Study

    Credits

    3 Contact Hour(s)

    Release Date

    Wednesday, December 3, 2014

    Offline Date

    Sunday, December 3, 2017

    ACPE Expiration Date

    Sunday, December 3, 2017

    Target Audience

    Pharmacist, Pharmacy Technician

    Cost

    $12.00

    • Overview

      Particularly in the area of sterile compounding, tragedy from medication error and adverse events related to compounded sterile products (CSPs) are major driving forces behind new guidance and legislation in pharmacy practice today.  In the last five years, there are far too many examples of highly publicized adverse events related to sterile compounding errors that serve both as tragic lessons and a call to improve the processes and techniques affecting the overall quality of CSPs. These events range from multistate fungal meningitis outbreaks to bacterial infections of the eye resulting in permanent vision loss and contaminated parenteral nutrition products leading to bacterial infection. This knowledge based program will focus on USP 797 and lessons learned from medication errors associated with CSPs, engaging the participant in both an account of recent contamination outbreaks and the ripple effect of changes occurring in the practice of compounding pharmacy today as a result of these errors.

       

      *This program is not intended to all inclusively cover USP 797 but rather, reveal aspects of USP 797 that impact the reduction of Medication Errors of Contamination.

       

      *This program does not qualify for Medication Errors in the state of FL

      Rating

         4.50  out of 5

      Handouts

      • Homestudy PDF :   SterileCompounding_HK(001).pdf

      Financial Support By

      PharmCon
    • Pharmacist

      Identify the four risk levels of compounded sterile products (CSPs).
      Describe examples of deviations from USP <797> associated with adverse events related to CSPs.
      List three required tests for personnel prior to compounding sterile products.
      Describe proper personnel cleansing and garbing requirements while compounding CSPs.
      Identify how compliance with USP <797> can prevent medication errors of contamination.

      Pharmacy Technician

      List three required tests for personnel prior to compounding sterile products.
      Describe proper personnel cleansing and garbing requirements while compounding CSPs.
      Describe examples of deviations from USP <797> associated with adverse events related to CSPs.
      Identify the four risk levels of compounded sterile products (CSPs).
      Identify how compliance with USP <797> can prevent medication errors of contamination.
    • Activity Type

      Knowledge

      CE Broker

      20-473445

      Universal Activity Number

      Pharmacist 0798-0000-14-187-H04-P
      Pharmacy Technician 0798-0000-14-187-H04-T

      ACPE PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

      PharmCon is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

      In order to obtain a Statement of Credit, participants must score no less than a 70% on the activity's test and complete a program evaluation.


    HARDWARE REQUIREMENTS
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
     
     


    SOFTWARE REQUIREMENTS
    Microsoft Edge
    Internet Explorer 8.0 or higher
    Google Chrome
    Safari
    Firefox 3.0.3 or higher
    Adobe Acrobat Reader


    NETWORK REQUIREMENTS
    Broadband Internet Connection:
    T1, Hi-speed DSL or Cable
    4G cellular connection
     
     
     

    This continuing education activity is held as copyright by PharmCon, Inc. Through this notice, PharmCon, Inc. grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).